| Issue Type | Login |
|---|---|
| Country | United Kingdom |
| Industry | Login |
| Region | Login |
| Maturity Date | 2035-09-25 |
| Par Value | 2000 |
| Callable | Login |
| Next Call Date | Login |
| Call Type | Login |
| Call Price (%) | Login |
| Series | Login |
| Class | Login |
| Maturity Structure | Login |
| Amount Outstanding (mil) | 900.00 |
| Coupon | 5.2 |
|---|---|
| Coupon Type | Login |
| Coupon Frequency | Login |
| First Coupon Date | Login |
| Last Coupon Date | Login |
| Sinking Fund | Login |
|---|---|
| Security | Login |
| Subordination | Login |
| Debt Type | Login |
| Issue Date | Login |
|---|---|
| Dated Date | Login |
| Issue Size (mil) | 900.000 |
| Min. Piece | Login |
| Min. Increment | Login |
This Royalty Pharma plc corporate note has a 5.20% fixed rate coupon paid on a Login basis. It was issued on MAR 12, 2000 with an issue size of 900.00 million USD and matures on September 25, 2035 with a last coupon date of FEB 28, 2020. |
Royalty Pharma plc, founded in 1996 and headquartered in New York City, is a leading buyer of royalty interests in innovative biopharmaceutical products. The company aims to provide investors with access to diverse, revenue-generating assets from established therapies and promising late-stage product candidates. Royalty Pharma's portfolio includes royalties from major pharmaceuticals such as AbbVie’s Imbruvica and Vertex's cystic fibrosis treatments, illustrating its strategic focus on high-value healthcare investments.